Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis

Area of Science:

• Hematology
• Pharmacology
• Clinical Therapeutics

Background:

• Lifelong transfusion-dependent β-thalassemia (lifelong TDβT) necessitates chronic blood transfusions, posing significant risks and complications.
• Hydroxyurea (HU), an oral chemotherapeutic agent, is being investigated for its potential to increase hemoglobin levels and mitigate transfusion burdens.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of hydroxyurea (HU) in patients with lifelong TDβT.
• To synthesize existing evidence on HU's impact on transfusion requirements and patient outcomes in lifelong TDβT.

Main Methods:

• A systematic literature search was conducted across MEDLINE, EMBASE, Cochrane databases, and conference proceedings.
• Eleven observational studies involving 859 patients were included in the analysis.
• Effect size was determined as the proportion of responders relative to the sample size.

Main Results:

• Hydroxyurea (HU) demonstrated a significant reduction in transfusion needs for lifelong TDβT patients.
• Complete response rates were 26% (95% CI, 13-41%), and overall response rates (≥50% reduction) were 60% (95% CI, 41-78%).
• No serious adverse effects were reported, although studies had limitations such as a lack of comparison groups.

Conclusions:

• Hydroxyurea (HU) appears to be an effective and well-tolerated treatment option for lifelong TDβT.
• Large-scale randomized clinical trials are recommended to definitively confirm these findings and establish HU's role in managing lifelong TDβT.